Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...

TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...

Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Racial and ethnic diversity is lacking in PsA clinical trials, with non-White participants remaining severely underrepresented.

IL-23 inhibitors appear safe for treating psoriasis in patients with a recent or past history of cancer, real-world data show.

Interleukin-6 inhibitors alone account for a significant share of that growth, but that segment remains largely dominated by big pharma companies like Roche, J&J, and Novo Nordisk. In contrast, the ...

Use of some interleukin inhibitors may be safer than methotrexate, other older systemic medications, anti-tumor necrosis factor biologics, and tofacitinib for serious infection risk in older adults ...